ARTICLE SUMMARY:
Cynthia Rice is chief mission strategy officer for JDRF, which is the leading global advocate for treatments and a cure for type 1 diabetes. She recently spoke to Market Pathways about important FDA developments in the push toward diabetes devices that can be used together seamlessly no matter the manufacturer, and she spotlighted reimbursement challenges these devices are facing.
Diabetes devices are treading new regulatory ground with recent approvals of interoperable devices—the Dexcom G6 continuous glucose monitor (Dexcom Inc.) and the t:Slim X2 (Tandem Diabetes Care)—and a submission in the works for an interoperable algorithm from health-tech non-profit start-up Tidepool.
JDRF’s Cynthia Rice discusses the interoperability efforts, as well as reimbursement challenges in the space with MTS Market Pathways.
